Summary: | 碩士 === 國立中興大學 === 生命科學院碩士在職專班 === 89 === 英文摘要
Alternative medicine has become very popular and attractive in recent decades. Ganoderma lucidum , one of the most widely used herbs, was reported to lower blood glucose level in animal studies. We therefore undertook a clinical study to investigate the effect of Ganoderma lucidum on fasting and postprandial blood glucose concentrations, fasting lipids levels, circulating oxidative stress and quality of life in subjects with type 2 diabetes mellitus.
We conducted a double blinded, placebo-controlled trial. There were 46 patients completed the trial. Subjects were randomized to take dry extract of Ganoderma lucidum 3000mg or placebo in addition to regular oral hypoglycemic agents for a period of 12 weeks. No differences were found in values of fasting glucose, HbA1c between placebo and Ganoderma lucidum group. Comparison of plasma glucose area under the curve during meal tolerance test between those of taking Ganoderma lucidum and placebo were significantly different (p<0.01, 2-way ANOVA). Changes in area under the glycemic curve in response to 4h mixed meals test were decreased 0.2±0.3 mg/dl.h for Ganoderma lucidum group and increased 45±42.1 mg/dl.h for placebo group, respectively (p<0.05). In those subjects with poor glycemic control, fasting plasma glucose decreased by 13.7% at 4weeks later (p<0.01 as compared with baseline), while it increased at 8 and 12 weeks. The Ganoderma lucidum lower mean blood pressure from 151±1.2 mmHg to 150.5±8.9 mmHg at 4 weeks, 146.0±5.4 mmHg at 8weeks, and 138.5±1.7 mmHg at 12 weeks. There were no change of total cholesterol and triglyceride values between placebo and Ganoderma lucidum treatment. In those with high baseline triglyceride , fasting triglyceride decreased 106±41.5 mg/dl for Ganoderma lucidum group and 0.2±0.1 mg/dl for placebo group (p<0.01between group). The values of circulating oxidative stress showed no significant change in both treatment group. Treatment by Ganoderma lucidum group showed significant improvement in subjective scoring for quality of life. The results of this study provide valuable information for supplemental therapy with Ganoderma lucidum in treating subjects with type 2 diabetes mellitus.
|